PTGX

Business Context and Reporting Period

Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Protagonist is an integrated discovery and development company focused on inflammation and immunology, hematology, and metabolic diseases. The company has no approved products and generates revenue solely through collaboration agreements with Johnson & Johnson (JNJ) and Takeda Pharmaceuticals.

Key Financial Metrics

Note: The company reported a net loss in 2025 compared to net income in 2024, primarily due to a significant decrease in collaboration revenue.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by 89% ($388.4 million) year-over-year. This was driven by the absence of the $165.0 million JNJ milestone payment recognized in Q4 2024 and the recognition of the bulk of the $300.0 million Takeda upfront payment in 2024. 2025 revenue consisted of $21.3 million from a Takeda milestone and $24.7 million for development services.
• Operating Expenses: Total operating expenses increased by 12% ($22.6 million). Research and Development (R&D) expenses rose 15% to $159.3 million, driven by increased pre-clinical and drug discovery costs for obesity candidates (PN-477, PN-458) and the IL-17 candidate (PN-881), partially offset by lower rusfertide clinical costs following the completion of the Phase 3 VERIFY trial.
• Liquidity: Cash and marketable securities increased by $86.8 million to $646.0 million, supported by positive operating cash flow despite the net loss.

Guidance, Outlook, and Risks

Outlook and Milestones

• Icotyde (JNJ): JNJ submitted NDAs to the FDA (July 2025) and EMA (September 2025) for psoriasis. Launch is expected in 2026 if approved. Protagonist is eligible for up to $630.0 million in future milestones and tiered royalties (6%-10%).
• Rusfertide (Takeda): NDA submitted to the FDA in December 2025 for polycythemia vera (PV). Launch expected in H2 2026. Protagonist expects to exercise its "opt-out" right in Q2 2026, converting the U.S. profit-share arrangement into worldwide royalties (14%-29%) and triggering up to $400.0 million in opt-out payments.
• Pipeline: Phase 1 trials initiated for PN-881 (IL-17 antagonist). IND-enabling studies ongoing for obesity candidates PN-477 and PN-458, and oral hepcidin candidate PN-8047.

Risks and Contingencies

• Regulatory Approval: No products are currently approved. Success depends on FDA/EMA approval of Icotyde and rusfertide.
• Collaboration Dependency: Future revenue is contingent on JNJ and Takeda successfully commercializing products and meeting milestones.
• Capital Requirements: Management believes current cash resources are sufficient for at least 12 months. Additional funding may be required for future pipeline advancement.
• Macroeconomic Factors: Risks include potential tariffs on pharmaceuticals, inflation, and geopolitical instability affecting clinical trial costs and supply chains.

Investor Verification Checklist

• Regulatory Decisions: Monitor FDA and EMA decisions on the Icotyde (psoriasis) and rusfertide (PV) NDAs filed in late 2025.
• Opt-Out Execution: Verify the timing and financial impact of Protagonist's expected Q2 2026 opt-out from the Takeda U.S. profit-share arrangement.
• Cash Burn Rate: Track quarterly cash usage to confirm the 12-month liquidity runway remains valid given the shift from milestone-driven revenue to operational expenses.
• Pipeline Progress: Review data readouts for PN-881 Phase 1 and IND filings for obesity candidates PN-477 and PN-458.
• Collaboration Terms: Confirm the specific royalty tiers and milestone triggers under the amended JNJ and Takeda agreements.